Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: J Pharmacol Exp Ther. 2008 May 6;326(2):555–562. doi: 10.1124/jpet.108.137703

Figure 1.

Figure 1

Target-mediated disposition model for denosumab pharmacokinetics. Drug administered subcutaneously gets absorbed (ka) into the plasma compartment (Cp, Vc). Drug can be eliminated (kel) or rapidly bind to the pharmacological target to form a drug-ligand complex (RC). The model also includes the internalization of the drug-ligand complex (kint).

HHS Vulnerability Disclosure